Autistic disorder. Autistic disorder
Conditions
Interventions
Intervention 1: Control group: Children with autism received daily risperidone (0.5 mg per day, and 0.5 mg added up to seven days, up to a maximum dose of 3 mg per day) and placebo for 10 weeks. Inter
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
5 Years to 11 Years
Inclusion criteria
Inclusion criteria: Diagnosis of autism based on DSM5 and ABC-C
Exclusion criteria
Exclusion criteria: Medically active disease The presence of another psychological diagnosis in DSM 3 axis History of previous sensitivity and intolerance to rosiglitazone History of seizures and liver disorders Taking antipsychotic drugs such as Risperidone before entering the study Alanine aminotransferase (ALT) level < 2.5 at the beginning of the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of irritability. Timepoint: Baseline and weeks 5, and 10. Method of measurement: By Aberrant Behavior Checklist-Community (ABC-C). | — |
Secondary
| Measure | Time frame |
|---|---|
| The severity of hyperactivity/noncompliance. Timepoint: Baseline and weeks 5, and 10. Method of measurement: By Aberrant Behavior Checklist-Community (ABC-C).;The severity of lethargy/social withdrawal. Timepoint: Baseline and weeks 5, and 10. Method of measurement: By Aberrant Behavior Checklist-Community (ABC-C).;The severity of stereotypic behavior. Timepoint: Baseline and weeks 5, and 10. Method of measurement: By Aberrant Behavior Checklist-Community (ABC-C).;The severity of inappropriate speech. Timepoint: Baseline and weeks 5, and 10. Method of measurement: By Aberrant Behavior Checklist-Community (ABC-C). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Shahin Akhondzadeh
Tehran University of Medical Sciences
Outcome results
None listed